Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

BACKGROUND: The RAS/RAF/MEK/ERK signalling pathway has a pivotal role in cancer proliferation and modulating treatment response. Selumetinib inhibits MEK and enhances effects of radiotherapy in preclinical studies. PATIENTS AND METHODS: Single-arm, single-centre, open-label phase I trial. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslett, K., Koh, P., Hudson, A., Ryder, W.D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., Faivre-Finn, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970011/
https://www.ncbi.nlm.nih.gov/pubmed/33748440
http://dx.doi.org/10.1016/j.ctro.2021.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970011/
https://www.ncbi.nlm.nih.gov/pubmed/33748440
http://dx.doi.org/10.1016/j.ctro.2021.02.008

Ejemplares similares